EUVIMEDEUVIMED entdecken
Crossref

Exploring Pathogenesis, Clinical Manifestations, and Management of Human Metapneumovirus Infection

Gaurao Damre, Snehal Sathe, Dhanashree Shinde, Vaibhav V Bhone

Journal of Pharmacy Practice and Community Medicine · 14.07.2026 · 12 (4) · 196-201

DOI: 10.5530/jppcm.20260049 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Pharmacy Practice and Community Medicine, online erschienen am 14.07.2026. Verfasst von Gaurao Damre und 3 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Human Metapneumovirus (HMPV), identified in 2001, is an emerging respiratory virus. Within the Pneumoviridae family, genus Metapneumovirus. This RNA virus is now recognised as a substantial cause of both upper along lower Respiratory Tract Infections (RTIs), affecting individuals belonging to all ages. While this virus may impact healthy adults, the most vulnerable populations include young children, infants, elderly adults, as well as immunocompromised individuals. Pathophysiology of HMPV involves its entry into respiratory epithelial cells, facilitated by viral Fusion (F), attachment (G) proteins. After entering the host cell, HMPV replicates in the cytoplasm, leading to the production of new virions that further propagate the infection. Both innate along adaptive components are essential to the complicated immune response to HMPV. Innate immunity, including pattern recognition receptors and natural killer cells, provides the first line of defence, while the adaptive immune response, consisting of T cells, antibodies, and B cells, is responsible for clearing the virus and offering long-term immunity. However, in severe cases, immune responses may contribute to lung injury, airway remodelling, and fibrosis, especially in individuals with pre-existing conditions or those experiencing prolonged infections. Clinically, HMPV infection varies from mild symptoms like cough, fever, as well as sore throat to more severe manifestations, for example, pneumonia, bronchiolitis, and respiratory failure. Supportive care, which includes hydration, is the main emphasis of management and rest, though antiviral treatments, for example, intravenous immunoglobulin, ribavirin, along with monoclonal antibodies, may be considered in severe cases.

Zitieren

APA

Damre, G., Sathe, S., Shinde, D., & Bhone, V. V. (2026). Exploring Pathogenesis, Clinical Manifestations, and Management of Human Metapneumovirus Infection. Journal of Pharmacy Practice and Community Medicine, 12(4), 196-201. https://doi.org/10.5530/jppcm.20260049

Vancouver

Damre G, Sathe S, Shinde D, Bhone VV. Exploring Pathogenesis, Clinical Manifestations, and Management of Human Metapneumovirus Infection. Journal of Pharmacy Practice and Community Medicine. 2026;12(4):196-201. doi:10.5530/jppcm.20260049

BibTeX
@article{Damre2026,
  author = {Damre, Gaurao and Sathe, Snehal and Shinde, Dhanashree and Bhone, Vaibhav V},
  title = {Exploring Pathogenesis, Clinical Manifestations, and Management of Human Metapneumovirus Infection},
  journal = {Journal of Pharmacy Practice and Community Medicine},
  year = {2026},
  volume = {12},
  number = {4},
  pages = {196--201},
  doi = {10.5530/jppcm.20260049}
}
Kostenlos starten →